Thursday, May 28, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result

Take-Two’s Record Guidance Hinges on November as Recurring Revenue Buys Time

Kennethcix by Kennethcix
May 28, 2026
in Uncategorized
0
Take-Two Stock
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

The math is simple on paper: deliver Grand Theft Auto VI on 19 November 2026, and Take-Two’s net bookings could vault to a record $8.2 billion. Miss the date again, and the stock’s recent slide risks accelerating.

Yet the market has already priced in a degree of skepticism. Shares closed at €188.00 last week, down roughly 8.3% from seven days earlier. The move came even after the company posted a strong fiscal fourth quarter—earnings per share of $0.80, well ahead of the $0.56 consensus, and net bookings of $1.58 billion, a whisker above expectations. For the full fiscal year 2026, net bookings reached $6.72 billion, up 19% year over year.

The real disconnect lies in the outlook. Take-Two guided for fiscal 2027 net bookings between $8.0 billion and $8.2 billion. Wall Street had been banking on roughly $9.1 billion. That gap—nearly a billion dollars—explains the bearish sentiment better than any chart pattern.

Recurring Revenue Provides a Floor

Take-Two’s business is far from a one-title gamble. In the latest quarter, player recurring spending accounted for 82% of total net bookings, and on a trailing twelve-month basis the figure sits at 78%. In-game purchases and subscriptions give the income statement a reliable backbone, regardless of whether GTA VI ships on schedule.

Still, the central thesis for investors hinges on that November window. The stock currently trades at about €190.90, roughly 15% below its 52-week high of €225.30 and 19% above its low of €160.40. The relative strength index of 59 suggests neutral territory—neither overbought nor oversold.

Should investors sell immediately? Or is it worth buying Take-Two?

Analyst Targets Stay Bullish Despite Guidance Miss

Major sell-side firms remain constructive. Wells Fargo recently trimmed its price target to $287, but that still implies upside of about 31% from current levels. UBS holds at $300, Wolfe Research at $289, and the consensus target hovers around $287.50. The stock is now about 16.6% below its 52-week peak and roughly 5.6% under its 200-day moving average.

The next catalyst is expected this summer, when Rockstar Games is widely anticipated to release a third trailer and open pre-orders. Research firm DFC Intelligence estimates that pre-order revenue alone could exceed $1 billion. Individual analysts project first-year sales of 31 million to 40 million units—numbers that could make or break the full-year guidance.

Execution Is Everything Now

With the original May 2026 launch date already scrapped—a move that barely rattled the stock (down just 1.0% on the day)—the company has no room for another slip. CEO Strauss Zelnick has locked in the 19 November release for PlayStation 5 and Xbox Series X|S, with no PC date announced yet.

If the summer marketing campaign delivers a compelling trailer and a record-breaking pre-order wave, the conservative guidance may start to look like deliberate under-promising. If not, the stock’s current valuation, already reflecting a hefty dose of doubt, could come under further pressure. Take-Two’s recurring revenue stream buys time, but the clock is now ticking toward November.

Ad

Take-Two Stock: Buy or Sell?! New Take-Two Analysis from May 28 delivers the answer:

The latest Take-Two figures speak for themselves: Urgent action needed for Take-Two investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 28.

Take-Two: Buy or sell? Read more here...

Tags: Take-Two
Kennethcix

Kennethcix

Related Posts

Assembly Biosciences Stock
Analysis

Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise

May 28, 2026
The Platform Group Stock
E-Commerce

The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums

May 28, 2026
Adidas Stock
Consumer & Luxury

Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

May 28, 2026
Next Post
Partners Group Stock

Partners Group Bets on Patient Capital with Total Return Strategy as $450B AUM Target Looms

Salesforce Beats, Sells Off: The AI Software Reckoning Begins

Salesforce Beats, Sells Off: The AI Software Reckoning Begins

T1 Energy Stock

Hedge Funds Buy, Trina Sells: T1 Energy Rides a 125% Monthly Rally While Facing a $50 Million Financing Hole

Recommended

Broker business

Unveiling the Future of Economic Freedom: Trends in Parallel Economy Conventions

2 years ago
Neutra Stock

Shifting Focus: How Neutra is Pivoting to Clinical Trial Management

2 months ago
TSMC Stock

TSMC Stock Surges on Dual Catalysts: Export License and Next-Gen Chip Progress

5 months ago
Lockheed Stock

Lockheed Martin Navigates Expansion and Legal Challenges

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Ubtech Robotics Bolsters Korean Alliance and Boardroom Grip Amid Humanoid Revenue Surge

Ferrexpo’s Double Squeeze: A Kyiv Court Battle and a $100 Million Funding Logjam Keep Shares Frozen

Refined Energy’s Uranium Push Gains Urgency as Board Shuffles and Drilling Progresses

AMD’s Trillion-Dollar Ambition Meets the $500 Ceiling: Strong Earnings Can’t Silence Profit-Takers

Navitas Semiconductor: A $6.7 Billion Bet on AI Data Centers With Only $8.6 Million in Quarterly Sales

Eli Lilly’s Two-Front Victory: A Trillion-Dollar Valuation and a Pharmacy Benefit Win Reshape the Obesity Landscape

Trending

Assembly Biosciences Stock
Analysis

Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise

by SiterGedge
May 28, 2026
0

Assembly Biosciences has emerged from the EASL Congress in Barcelona with more than just data. The biotech...

The Platform Group Stock

The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums

May 28, 2026
Adidas Stock

Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

May 28, 2026
Ubtech Robotics Stock

Ubtech Robotics Bolsters Korean Alliance and Boardroom Grip Amid Humanoid Revenue Surge

May 28, 2026
Ferrexpo Stock

Ferrexpo’s Double Squeeze: A Kyiv Court Battle and a $100 Million Funding Logjam Keep Shares Frozen

May 28, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Assembly Biosciences Strengthens Pipeline and Balance Sheet After $115M Upsized Raise
  • The Platform Group’s EBITDA Surges 37%, but a Perfect Storm of Headwinds Keeps the Stock in the Doldrums
  • Adidas Transforms into a Data Powerhouse as World Cup Orders Pour In

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com